Radcliffe Department of Medicine

Chakraverty Group: Haematopoietic Transplantation and Immunotherapy

Our group is interested in developing novel immunotherapeutic approaches for leukaemia. Clinical approaches currently used include allogeneic haematopoietic stem cell transplantation, chimeric antigen receptor T cell therapy and immune checkpoint inhibitors. While each of these approaches can be successful, they also fail in many patients as a result of tumour adaptations or diminished function of immune cells. Enhanced immunity can also lead to immune-related adverse events due to on- or off-target effects. We are exploring the mechanisms that underpin these failures and using this information to devise new strategies that can be translated into early phase clinical trials.

Psaila Group: Normal and Malignant Megakaryocyte/Platelet Biology

We are interested in (1) Applying state-of-the-art single cell approaches to study normal and malignant megakaryocyte biology and bone marrow fibrosis, to identify new targets for therapy for patients with myeloproliferative neoplasms; and (2) The role of platelets as biomarkers for early cancer detection.

Chapman Group: Recombination mechanisms in immunity and cancer

de Bruijn Group: Developmental Haematopoiesis

We study the embryonic origins of blood stem cells with the aim to inform the generation of these cells in culture, and ultimate produce clinically relevant blood stem cells for therapeutic purposes.

Higgs Group: Laboratory of Gene Regulation

We use state-of-the-art laboratory and computational approaches to understand how mammalian genes are switched on and off during development and differentiation and how this goes awry in human genetic diseases.

Mead Group: Haematopoietic Stem Cell Biology

The Haematopoietic Stem Cell Biology (HSCB) Laboratory is focused on understanding how the normal haematopoietic stem/progenitor hierarchy is disrupted during the development of myeloid malignancies. Our overarching aim is to improve the management of myeloproliferative neoplasms and related conditions through better monitoring and therapeutic targeting of malignant stem cell populations.

Vyas Group: Normal and Leukaemic Blood Stem/Progenitor Cell Biology

We aim to understand the fundamental biological processes underlying normal and malignant haematopoiesis and translate this to improve patient outcomes through new rational therapies.

Hughes Group: Genome Biology

Using genomics, computational and synthetic biology approaches to understand how genes are regulated in health and disease.

Porcher Group: Molecular Dissection of Blood Cell Fate Determination

We study the developmental origin and trajectory of the blood stem cell lineage, and the transcriptional and epigenetic mechanisms underlying specification of this lineage from mesoderm. We use this information to model development of blood stem cells in vitro for regenerative medicine purposes.

Milne Group: Epigenetics and Gene Regulation in Leukaemia

Aberrant epigenetic changes are a driving force in many human cancers. The focus of our lab is centred on understanding how epigenetics impacts gene regulation so that this information can potentially be used to develop new therapeutic strategies.

Gibbons Group: ATRX Group

We are interested in the function of the chromatin remodelling factor ATRX and how mutations in this factor lead to human disease.

Nerlov Group: Hematopoietic Stem Cell Genetics

Hematopoietic stem cell (HSC) transplantation is the only stem cell therapy in routine clinical use, and it is also the cell type that gives rise to most blood cancers. We use single cell biology and genetics to understand how hematopoietic stem cells normally sustain blood formation, and how this process is altered during ageing and when leukemia develops.

Search results

Found 12 matches for